Galenical formulations of Aliskiren and Valsartan

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the p...

Full description

Saved in:
Bibliographic Details
Main Authors MAGGY BABIOLE SAUNIER, BRUNO BUSS, MARIERISTINE WOLF, PATRICE FRANCOIS KELLER, NICOLETTA LOGGIA, CHARU KOCHHAR, SHOUFENG LI, HONG WEN, SABINE ADLER, INDRAJIT GHOSH, STEFAN HIRSCH, JAY PARTHIBAN LAKSHMAN, JULIEN TAILLEMITE, CATHERINE CURDY, MICHAELA ANNA MARIA BOCK, AMOL SINGH MATHARU, RALF ALTENBURGER, JAMES KOWALSKI, NICOLE BARGENDA, WEI-QIN TONG, SUDHA VIPPAGUNTA
Format Patent
LanguageEnglish
Published 09.04.2009
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.
Bibliography:Application Number: AU20080309058